

Foundation for Angelman Syndrome Therapeutics (FAST) Grant-In-Aid program

PURPOSE

FAST's grants and fellowship programs aim to encourage therapeutic translational research agendas focusing on potential treatments, research, or biomarker and outcome measure development that will greatly enhance the progress of these platforms toward human benefit for Angelman syndrome (AS).

FAST is committed to supporting individuals living with Angelman syndrome, and their caretakers, to realize their full potential and bring scientific and therapeutic advancements that help to translate to the human condition.

The goal is to bring potential treatments to current medical practice as quickly and safely as possible; therefore, preference will be given to research projects that have a translational application to human benefit, and the results of all of FAST funded research will be shared with the community in a timely fashion through publications and presentations. If publication is with a journal that is not open access, we ask that the PI provide a detailed lay summary that can be posted on the FAST website. Additionally, FAST aims to fund research that can serve as a launching pad, or bridge, which can lead to further research support from other government agencies and funding sources.

The Grant-In-Aid program will provide targeted funding to enable research projects on Angelman syndrome to proceed at a rapid pace. These one-time awards are not meant to be the sole support for a research project, but are, instead, envisioned to enable capitalization upon findings from current projects, allow for exploratory experiments, or provide funding for reagents or equipment necessary to move research forward.

KEY DATES

All grant applications have a rolling deadline. Please contact: grants@cureangelman.org for more information and provide a letter of intent if you are considering applying for a grant.

ELIGIBILITY

Institutions receiving grants must be recognized as nonprofit. In the US, this means institutions that do not operate to make a profit. Individuals should have training and experience at least equal to the Ph.D. or M.D. level. Awardees are required to pursue their research and academia on a full-time basis or as specified by the sponsoring institution in accordance with its own policies.

DURATION OF SUPPORT and ALLOWABLE COSTS

Grants-in-Aid are one time awards. A financial report and progress report are required within one year of the award activation date.

There is no predetermined amount of award. We anticipate investigators applying for what they need. However, only under special circumstance do we anticipate awards in excess of \$10,000. Applicants are encouraged to contact FAST at grants@cureangelman.org to determine the feasibility of a potential request prior to applying.

Potential allowable costs include:

Reagents and Materials: These may include but are not limited to: gene chips, chemical libraries, acquisition of cell lines, acquisition of animal model lines.

Services: These may include, but are not limited to: genetic sequencing, proteomics, metabolomics, mass spectrometry, antibody production, and drug/chemical manufacturing.

Equipment: FAST will consider the purchase of specialized pieces of equipment or software purchases for specific projects when necessary.

Costs that are not allowable:

- 1) Salaries
- 2) Fringe Benefits
- 3) Indirect Costs
- 4) General office supplies/equipment
- 5) Bridging funds to cover gaps in grant funding

APPLICATION and SUBMISSION INFORMATION

Applicants should prepare a one-page Letter of Intent and include the following:

- 1) **Hypotheses and specific Aims:** Include specific research questions, objectives and hypotheses. The focus of the applications should be aligned with the FAST mission.
- 2) **Lay summary:** This should include your research objectives and the potential your work has to help those with Angelman syndrome. The lay summary should be easily interpreted by a lay person. We are committed to educating the public about the importance of this research, the this lay summary is an important part of the application process. This will be posted on the FAST website if the project is funded.
- 3) **Budget**
 - i) Detailed budget, keeping in mind what costs are allowable and not allowable.
- 4) **Biosketch:** The biosketch of the PI and any collaborative personnel for the project should be included but does fall within the 1 page limit. Please use current NIH Biosketch Format.
- 5) **Formatting**
 - i) Proposal in Arial or Times New Roman size 11 point font, single or 1.15 spacing;
 - ii) Margins no less than 0.5”;
 - iii) Include a header on each page indicating name of PI (Last, First), page number;
 - iv) Figures and figure legends may be included and do not fall within the 1 page limit; and
 - v) Only PDF files accepted for review.

Submit application materials

Applications should be submitted electronically to grants@cureangelman.org Only PDF files will be accepted and reviewed. Applications will be accepted on a rolling basis. Any questions about the application process should be directed to grants@cureangelman.org.

HUMAN AND ANIMAL SUBJECTS

Human subjects studied in the course of research conducted under a research award are under no circumstances the responsibility of FAST. Human subjects in a program supported by FAST shall be volunteers in any survey, study, or procedure. FAST requires recipients of any award using human

subjects to demonstrate institutional review board (IRB) approval of the research project prior to dispersal of the awarded funds. If IRB approval cannot be obtained within 6 months of the award, the award may be rescinded by the Board of Directors.

If animals are used in the proposed study, written certification must be provided to FAST indicating that proper treatment, care, and humane conditions will be provided. FAST requires recipients to demonstrate Institutional Animal Care and Use Committee (IACUC) approval of the research project prior to dispersal of award funds.

FAST GRANT REVIEW PROCESS

The first stage of providing fair and expert review for research funding applications submitted to FAST consists of scientific peer review by a group of highly esteemed basic and clinical scientists and clinicians that form our **Scientific Advisory Board (SAB)**. The panel uses standard guidelines established by the National Institutes of Health (NIH) for scoring applications with an emphasis on innovation, scientific rigor, and relevance to the mission of FAST. All reviewer conflicts of interest must be revealed prior to the review. All members of the SAB have signed a nondisclosure/confidentiality agreement. If the SAB Chair deems there to be a conflict of interest, the SAB member in conflict will be recused from the review process. Conflicts of interest include, but are not limited to, employment at the same sponsoring institution and collaboration on recent or current research projects, competing research proposal for the same request for proposal (RFP), and anything else that the chair of the SAB determines to be a conflict.

Applicants undergo scientific peer-review by the SAB and will receive scores based on scientific merit, innovation, translational impact and alignment with FAST's mission. Applications will also be reviewed based on the experimental design, methods, rationale budget, and feasibility. Applicants should concisely and adequately detail how the hypotheses will be tested, demonstrating adequate power for testing the hypothesis, and clearly define all variables and aims. If SAB critiques have follow-up questions or recommendations, Applicant will provide a response to each question and/or recommendation. The SAB recommendations are then reviewed and compiled by the Scientific Director Panel. This panel consists of the Chair of the SAB, the CSO and the Science Director. All recommendations for funding are made by the panel to the FAST Board of Directors (BOD). Panel funding recommendations are based on scientific merit (as evaluated by the SAB), budgetary considerations and discussion of relevancy and priority to the mission of FAST. Final approval is required by the FAST BOD before funding may occur.

FAST strives to review and give a funding response to all submitted grants within six weeks of receiving the grant submission. This allows for the grants to be initially reviewed and for any concerns raised by the SAB to be properly addressed by the Applicant before final funding decisions are made.

No-Cost Extensions and Carryover Policy

A no-cost extension extends the project period beyond the original project end date. No additional funding will be allowed. A no-cost extension may be requested if there is a programmatic need to continue the research and there are sufficient funds. A no-cost extension request should be made at least 30 days prior to the end of the project period and must be requested by the PI detailing the amount being requested, the cause for such request and the date in which the extension would end.

A carryover allows unobligated funds remaining at the end of the budget period to be carried forward to the next budget period. The carryover would allow the grantee to use the unused prior year funds in a following budget period. A carryover request should be made at least 30 days prior to the end of the project period and must be requested by the PI detailing the amount to be carried over, explanation of unobligated balance, detailed budget and scientific justification. A carryover request will only be allowed for grants longer than one year.

Prohibition of Discrimination

No person shall be excluded from participation in or denied the benefits of any program or activity receiving financial assistance from FAST because of race, ethnic origin, religion, age, sex or sexual orientation.

Amendment of Policies

FAST reserves the right to modify its policies governing research awards at any time. The recipient agrees to abide by any changes or to terminate the grant at the time when such changes become effective. Failure to abide by the policies governing awards shall be considered sufficient grounds for cancellation of an award or refusal to consider any pending application by the grantee.